Tandem Diabetes Care (TNDM) to Release Quarterly Earnings on Wednesday

Tandem Diabetes Care (NASDAQ:TNDM) will announce its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, August 1st. The medical device company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Tandem Diabetes Care had a negative net margin of 17.15% and a negative return on equity of 41.54%. The business had revenue of $221.90 million during the quarter, compared to analysts’ expectations of $205.63 million. During the same period last year, the company posted ($0.30) EPS. The business’s revenue was up 13.3% on a year-over-year basis. On average, analysts expect Tandem Diabetes Care to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ:TNDM opened at $31.91 on Monday. Tandem Diabetes Care has a 52 week low of $13.82 and a 52 week high of $53.69. The stock has a market capitalization of $2.09 billion, a P/E ratio of -15.27 and a beta of 1.36. The firm has a fifty day simple moving average of $39.89 and a two-hundred day simple moving average of $41.90. The company has a quick ratio of 2.38, a current ratio of 3.05 and a debt-to-equity ratio of 1.31.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Tandem Diabetes Care in a research note on Friday, October 4th. They set a “neutral” rating and a $46.00 price target for the company. Barclays lifted their price objective on shares of Tandem Diabetes Care from $55.00 to $58.00 and gave the company an “overweight” rating in a report on Monday, August 5th. Robert W. Baird lifted their price objective on shares of Tandem Diabetes Care from $36.00 to $39.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. Piper Sandler restated an “overweight” rating and issued a $55.00 price target (up previously from $50.00) on shares of Tandem Diabetes Care in a report on Friday, August 2nd. Finally, Royal Bank of Canada assumed coverage on shares of Tandem Diabetes Care in a report on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Tandem Diabetes Care has an average rating of “Moderate Buy” and a consensus price target of $55.13.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.